HERA Trial: Invasive Lobular Breast Carcinoma Patients Derived Same Benefit From Trastuzumab Maintenance

In the HERA trial, benefit for invasive lobular breast cancer patients with 1 year of trastuzumab maintenance was similar to invasive ductal carcinoma patients.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsMRI is the best predictor of tumor size in breast cancer. Histologic type and tumor size are key parameters when estimating tumor size and should be taken into account when planning surgery. Patient age does not interfere with the interpretation of imaging tests.ResumenIntroducciónEl objetivo de este estudio fue evaluar qué prueba de imagen de las empleadas para medir el tamaño del cáncer de mama primario preoperatorio (mamografía, ecografía o resonancia magnética (RM)) se correlacionó mejor con el tamaño del tumor en la pieza quirúrgica posto...
Source: Cirugia Espanola - Category: Surgery Source Type: research
Abstract BACKGROUND: This randomized controlled trial aimed to investigate the effects of circumferential shaving on reducing the intraoperative margin positivity rate (MPR) during breast-conserving surgery (BCS). METHODS: Eligible breast cancer patients were randomly assigned into no-shave and shave groups. In the no-shave group, the cavity margins were collected for assessment after the tumor resection, whereas in the shave group, a circumferential shaving was performed before collecting the cavity margins. The primary outcome was the intraoperative MPR by frozen section analysis. RESULTS: A total of 1...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
Breast conserving surgery (BCS) followed by radiation therapy (RT) is the primary management for many women with early-stage, invasive breast cancer and ductal carcinoma in situ (DCIS) [1 –4]. Most women achieve good to excellent cosmesis after BCS and RT but some experience cosmetic failure, defined as fair or poor cosmetic outcomes [5–17]. However, comparisons of cosmetic outcomes across international jurisdictions using contemporary surgical and RT techniques for DCIS are lack ing.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Conclusion.This retrospective analysis suggests that eribulin demonstrates similar efficacy in patients with ILC and IDC with metastatic disease who have previously received an anthracycline and a taxane.Implications for Practice.Data on the efficacy of chemotherapy regimens in patients with advanced invasive lobular carcinoma (ILC) of the breast are limited. This pooled retrospective analysis of three clinical studies demonstrates that the magnitude of benefit of eribulin in the metastatic setting did not differ between patients with ILC versus invasive ductal carcinoma (IDC), even when restricting for patients with estro...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Conclusions: The ADC-min values are significantly different among IDC, IDC-DCIS, and DCIS, with the lowest ADC-min values in IDC, followed by IDC-DCIS and DCIS. The ADC-min maybe used as a promising parameter to differentiate DCIS and invasive cancer.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients. PMID: 31409615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
In conclusion, the presence of calcifications and vascularity on sonography or a lager distribution of calcifications on mammography may suggest DCISM. PMID: 31396390 [PubMed]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer.The new system,described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists.“It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments,” said Dr. Joann Elmore, the study’s senior author ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
In 13 –50%, Ductal Carcinoma In Situ (DCIS) progresses to an Invasive Ductal Carcinoma (IDC). As the individual progression risk from DCIS to IDC cannot be estimated based on clinical parameters or biomarkers, all patients with DCIS are medically treated equally. However, the role of tumor microenvironm ent and especially of tumor-associated fibroblasts (TAFs) appears to be critical for progression from DCIS to IDC. Based on previous work by Sameni et al. (2012), the aim of this study was to establish a 3D co-culture of primary fibroblasts and DCIS cells in vitro as a model for further investigatio ns of TAFs’ ...
Source: Maturitas - Category: Primary Care Authors: Tags: LBO03 Source Type: research
ConclusionMetabolic imaging could help to identify the subgroup of indolent lesions from those potentially aggressive ones that may be managed by active surveillance.Key Points• Low- and high-grade DCIS likely arise from two distinct evolutionary paths and when low-grade lesions progress to invasive cancer, the tumor is frequently low grade and well differentiated.• Ongoing clinical trials evaluate whether patients with low-risk DCIS could be safely managed by an active surveillance approach, with avoidance of unnecessary treatments and without impact on ipsilateral invasive breast cancer free survival time.&bull...
Source: European Radiology - Category: Radiology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Ductal Carcinoma | Herceptin